Elan increases sales by 19%:
This article was originally published in Clinica
Turnover at drug delivery company Elan has grown 19% to I£141.7 million ($223 million) in the 12 months to March. Net income rose 35% to I£56.4 million. Based in Dublin, Ireland, Elan expects its pending stock swap acquisition of Athena Neurosciences to close by the end of June (Clinica No 698, p 1).
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
In second letter this year targeting email communications, OPDP says that putting the methotrexate oral solution’s risk information below the signature block does not offer ‘prominence and readability’ comparable to the information on the drug’s effectiveness for the treatment of acute lymphoblastic leukemia that was in the body of the email.